Loading clinical trials...
Loading clinical trials...
A Randomized, Open-label, Active-controlled Multi-center Study to Assess Safety of Uninterrupted Rivaroxaban vs. Usual Care in Subjects Undergoing Catheter Ablation Therapy for Atrial Fibrillation
Conditions
Interventions
rivaroxaban
uninterrupted vitamin K antagonist (VKA)
Locations
44
United States
Beverly Hills, California, United States
Los Angeles, California, United States
Sacramento, California, United States
San Francisco, California, United States
Jacksonville, Florida, United States
Maywood, Illinois, United States
Start Date
February 1, 2013
Primary Completion Date
October 1, 2014
Completion Date
October 1, 2014
Last Updated
March 6, 2017
NCT05147792
NCT06935591
NCT05963698
NCT03546374
NCT04947657
NCT06686485
Lead Sponsor
Janssen Scientific Affairs, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions